Ceftazidime and Hypocalcaemia - a phase IV clinical study of FDA data

Summary:

Hypocalcaemia is reported as a side effect among people who take Ceftazidime (ceftazidime), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Bactrim, and have Hyperuricaemia.

The phase IV clinical study analyzes which people have Hypocalcaemia when taking Ceftazidime. It is created by eHealthMe based on reports of 10,307 people who have side effects when taking Ceftazidime from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Hypocalcaemia?

Hypocalcaemia (levels of calcium in blood serum are abnormally low) is found to be associated with 1,199 drugs and 1,302 conditions by eHealthMe. Check the latest studies of Hypocalcaemia.

On Aug, 01, 2026

10,307 people reported to have side effects when taking Ceftazidime.
Among them, 56 people (0.54%) have Hypocalcaemia.

Among these 56 people:

How long have people been on Ceftazidime when they have Hypocalcaemia? *

What is the gender of people who have Hypocalcaemia when taking Ceftazidime? *

female: 14.81 %
male: 85.19 %

What is the age of people who have Hypocalcaemia when taking Ceftazidime? *

What are other drugs people take besides Ceftazidime? *

Bactrim: 35 people, 62.50%
Amlodipine: 27 people, 48.21%
Imbruvica: 24 people, 42.86%
Ibrutinib: 15 people, 26.79%
Allopurinol: 12 people, 21.43%
Budesonide: 11 people, 19.64%
Trimethoprim: 10 people, 17.86%
Ciprofloxacin: 10 people, 17.86%
Valacyclovir Hydrochloride: 9 people, 16.07%
Enoxaparin Sodium: 8 people, 14.29%

What are other side effects people have besides Hypocalcaemia? *

Hyperkalemia (damage to or disease of the kidney): 35 people, 62.50%
Oedema Peripheral (superficial swelling): 34 people, 60.71%
Diarrhea: 34 people, 60.71%
Respiratory Distress (difficulty in breathing): 33 people, 58.93%
Hypertensive Crisis: 33 people, 58.93%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 32 people, 57.14%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 32 people, 57.14%
Death: 31 people, 55.36%
Haematotoxicity (toxins that destroy red blood cells): 31 people, 55.36%
Pressure Ulcer: 28 people, 50.00%

What are the existing conditions these people have? *

Asthma: 33 people, 58.93%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 33 people, 58.93%
Glaucoma (increased fluid pressure in the eye with vision loss): 33 people, 58.93%
Infection: 33 people, 58.93%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 33 people, 58.93%
Haematotoxicity (toxins that destroy red blood cells): 30 people, 53.57%
High Blood Pressure: 30 people, 53.57%
Fever: 9 people, 16.07%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 7.14%
Sedation: 4 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and have Hypocalcaemia?

- Check whether Hypocalcaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftazidime:

Ceftazidime (10,327 reports)

Hypocalcaemia treatments and more:

Hypocalcaemia (26,346 reports)

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypocalcaemia:

Hypocalcaemia (1,199 drugs)

Browse all the conditions that are associated with Hypocalcaemia:

Hypocalcaemia (1,302 conditions)

Related publications that referenced our studies

Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .
Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Ceftazidime) and Ceftazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.